

25 May 2022

ASX Announcement

Firebrick Appoints Dr Richard Treagus as Director

- **Dr Richard Treagus is an important appointment to the FRE board**
- **Dr Treagus is a medical doctor with extensive ASX experience and a valuable background in pharmaceutical sales and marketing**
- **Most recently, Dr Treagus was Executive Chairman of Neuren Pharmaceuticals (ASX: NEU), a successful Australian biotech company**

Firebrick Pharma Limited (ASX:FRE) (Company or Firebrick) is pleased to announce the appointment of Dr Richard Treagus as a non-executive director on the Firebrick board of directors, with effect from 1 June 2022.

"We have had ongoing discussions with Richard about Firebrick since the Company was founded and are excited that he has agreed to join our board," said Firebrick Executive Chairman, Dr Peter Molloy. "Richard brings valuable insights, not only as a medical doctor and very experienced director, but as someone with expertise in OTC pharmaceutical marketing."

Dr Treagus was previously Commercial Director for Aspen Pharmacare in South Africa, responsible for sales and marketing of pharmacy and consumer products. More recently, from 2006 to 2012, he was CEO of Acrux Limited (ASX:ACR), which grew 10-fold in value during his tenure and from 2013 to 2020, he was Executive Chairman of Neuren Pharmaceuticals Limited (ASX:NEU), which grew 6-fold in value during his tenure.

Dr Treagus said: "Firebrick is a great example of a late-stage innovative Australian pharmaceutical company, developing a novel medical treatment for a widespread and costly medical condition. I look forward to supporting the Firebrick team as they move Nasodine through Phase 3 and towards marketing approval in the major global markets."

In the Firebrick prospectus (p. 42), the Company indicated that after listing it intended to appoint an additional independent non-executive director with skills and expertise that complement the members of the existing Board. From 1 June, the Firebrick board will comprise four directors: The founders, Dr Stephen Goodall and Dr Peter Molloy, plus two non-executive directors, with Dr Treagus joining Dr Phyllis Gardner as the second non-executive director. Dr Gardner is a Professor of Medicine at Stanford University and is also on the Board of Fellows of Harvard Medical School.

Subject to shareholder approval at the Annual General Meeting to be held in November 2022, the Company intends to grant Dr Treagus 100,000 Options with an expiry date which is four (4) years after the Options are granted and an exercise price equivalent to a 43% premium to the five day volume weighted average market price of the Company's shares at time of approval.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Dr Richard Treagus

Between 1990 and 1997, Dr Treagus graduated with an MB ChB (Medicine and Surgery, First class with Honours), MPharmMed (Master of Medicine) and an MBA (Master of Business Administration) from universities in South Africa. After a period as Medical Director for Wyeth-Ayerst (now Pfizer), in 1998 he became Commercial Director of Aspen Pharmacare in South Africa, where he was responsible for all sales, marketing and business development for pharmacy and consumer products. Between 2002 and 2006, he was General Manager of Sigma Pharmaceuticals in Melbourne, responsible for all sales, marketing and business development, then from 2006 to 2012 was Managing Director and CEO of Acrux (ACR), the market value of which increased 10-fold during his tenure. Between 2013 and 2020, he was Executive Chairman of Neuren Pharmaceuticals (NEU), and its market value increased 6-fold during his tenure.

About Firebrick Pharma

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold. The Company also owns a patent family that covers the use of intranasal povidone-iodine for the prevention of pandemic viral diseases, including COVID-19. Firebrick is currently undertaking two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com